You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 167 No. 17, September 24, 2007 TABLE OF CONTENTS
  Archives
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Oncology
 •Diagnosis
 •Alert me on articles by topic

Biomarkers for the Early Detection of Cancer

An Inflammatory Concept

Hemant K. Roy, MD; Janardan D. Khandekar, MD

Arch Intern Med. 2007;167(17):1822-1824.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The continued high mortality toll from cancer reflects, in part, the inability to provide comprehensive screening for the entire at-risk population. The ideal cancer screening test not only needs to be highly accurate but also must foster patient compliance in that discomfort, embarrassment, and expense present formidable barriers to screening. Of the myriad modalities currently available (eg, radiography and endoscopy), serum biomarkers hold the greatest promise with regard to patient acceptability.1 Biomarkers generally identify the presence of malignancy by means of (1) circulating tumor components, (2) proteins elaborated by tumor, or (3) host response to the tumor (eg, immunologic). To date, the most commonly used serum screening tests (such as {alpha}-fetoprotein, CA-125, and prostate-specific antigen for hepatocellular, ovarian, and prostate cancer, respectively) have generally focused on the former 2 categories. However, these tests have many problems, including low sensitivity for early-stage, curable . . . [Full Text of this Article]


AUTHOR INFORMATION

RELATED ARTICLE

Prospective Study of Leukocyte Count as a Predictor of Incident Breast, Colorectal, Endometrial, and Lung Cancer and Mortality in Postmenopausal Women
Karen L. Margolis, Rebecca J. Rodabough, Cynthia A. Thomson, Ana Maria Lopez, Anne McTiernan, and for the Women's Health Initiative Research Group
Arch Intern Med. 2007;167(17):1837-1844.
ABSTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Colorectal Cancer Risk: Black, White, or Shades of Gray?
Roy and Bianchi
JAMA 2008;300:1459-1461.
FULL TEXT  

Epidemiology of Cytokines: The Women On the Move through Activity and Nutrition (WOMAN) Study
Wong et al.
Am J Epidemiol 2008;168:443-453.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.